M&A
confidence high
sentiment neutral
materiality 0.60
Lexeo completes acquisition of Mantle Therapeutics for $5.3M cash and $3M stock plus contingent payments
Lexeo Therapeutics, Inc.
- Lexeo completed the Mantle Therapeutics acquisition on September 29, 2026, through the merger of Magma Merger Sub Inc. into Mantle.
- Upfront consideration was $5.3 million in cash and $3.0 million in Lexeo common stock, issued under Section 4(a)(2)/Regulation D exemption.
- Contingent payments include a $1.0 million additional cash payment and up to $12.0 million in milestone payments over 12 years tied to development and regulatory milestones.
- Mantle restricted stock vested and was cancelled, and Mantle SAFEs and convertible promissory notes were cancelled for applicable consideration or payoff.